PriceTargets.com logo

NASDAQ:ORIC - ORIC Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $22.00
  • Forecasted Upside: 367.09 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$4.71 As of 08/15/2022 01:00 AM ET
▼ -0.13 (-2.69%)

This chart shows the closing price for ORIC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ORIC Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ORIC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ORIC

Analyst Price Target is $22.00
▲ +367.09% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for ORIC Pharmaceuticals in the last 3 months. The average price target is $22.00, with a high forecast of $31.00 and a low forecast of $9.00. The average price target represents a 367.09% upside from the last price of $4.71.

This chart shows the closing price for ORIC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 5 polled investment analysts is to hold stock in ORIC Pharmaceuticals. This rating has held steady since March 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
2/22/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
5/23/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/21/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/19/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/17/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
5/18/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
7/17/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
8/16/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/15/2022OppenheimerInitiated CoverageHoldLow
5/20/2022CitigroupLower Price TargetBuy$9.00Low
4/4/2022CitigroupUpgradeNeutral ➝ Buy$7.00 ➝ $10.00High
3/25/2022HC WainwrightDowngradeBuy ➝ NeutralMedium
3/22/2022GuggenheimDowngradeBuy ➝ NeutralHigh
3/22/2022CitigroupDowngradeBuy ➝ Neutral$22.00 ➝ $7.00High
3/22/2022OppenheimerDowngradeOutperform ➝ Market PerformHigh
11/10/2021HC WainwrightBoost Price TargetBuy$30.00 ➝ $31.00Medium
10/8/2021Robert W. BairdLower Price TargetOutperform$47.00 ➝ $26.00High
10/8/2021CitigroupLower Price TargetBuy$33.00 ➝ $22.00High
10/8/2021HC WainwrightReiterated RatingBuy$53.00 ➝ $30.00High
9/23/2021HC WainwrightReiterated RatingBuy$53.00Low
8/11/2021HC WainwrightLower Price TargetBuy$54.00 ➝ $53.00High
7/6/2021CitigroupUpgradeNeutral ➝ BuyHigh
6/29/2021HC WainwrightReiterated RatingBuy$54.00High
6/6/2021Robert W. BairdReiterated RatingBuy$45.00High
3/25/2021HC WainwrightBoost Price TargetBuy$52.00 ➝ $54.00Low
1/25/2021CitigroupDowngradeBuy ➝ Neutral$34.00Low
11/9/2020HC WainwrightReiterated RatingBuyLow
8/12/2020Robert W. BairdInitiated CoverageOutperform$45.00Low
8/6/2020CitigroupUpgradeNeutral ➝ Buy$35.00High
8/3/2020HC WainwrightInitiated CoverageBuy$52.00High
6/19/2020OppenheimerReiterated RatingBuy$48.00High
6/11/2020OppenheimerInitiated CoverageMarket Perform$48.00High
5/19/2020JPMorgan Chase & Co.Initiated CoverageOverweight$40.00Low
5/19/2020Jefferies Financial GroupInitiated CoverageBuy$40.00Low
5/19/2020CitigroupInitiated CoverageNeutral$35.00Low
5/19/2020GuggenheimInitiated CoverageBuy$45.00Low
(Data available from 8/16/2017 forward)

News Sentiment Rating

-0.46 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/18/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/17/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/19/2022
  • 3 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 4 very negative mentions
Mentions as of
4/18/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
5/18/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/17/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/17/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/16/2022

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
ORIC Pharmaceuticals logo
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $4.71
Low: $4.57
High: $4.83

50 Day Range

MA: $4.31
Low: $3.60
High: $5.24

52 Week Range

Now: $4.71
Low: $2.62
High: $26.70

Volume

60,141 shs

Average Volume

167,758 shs

Market Capitalization

$186.42 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.06

Frequently Asked Questions

What sell-side analysts currently cover shares of ORIC Pharmaceuticals?

The following Wall Street sell-side analysts have issued stock ratings on ORIC Pharmaceuticals in the last twelve months: Citigroup Inc., Guggenheim, HC Wainwright, Oppenheimer Holdings Inc., and Robert W. Baird.
View the latest analyst ratings for ORIC.

What is the current price target for ORIC Pharmaceuticals?

3 Wall Street analysts have set twelve-month price targets for ORIC Pharmaceuticals in the last year. Their average twelve-month price target is $22.00, suggesting a possible upside of 367.1%. HC Wainwright has the highest price target set, predicting ORIC will reach $31.00 in the next twelve months. Citigroup Inc. has the lowest price target set, forecasting a price of $9.00 for ORIC Pharmaceuticals in the next year.
View the latest price targets for ORIC.

What is the current consensus analyst rating for ORIC Pharmaceuticals?

ORIC Pharmaceuticals currently has 3 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ORIC, but not buy more shares or sell existing shares.
View the latest ratings for ORIC.

What other companies compete with ORIC Pharmaceuticals?

Other companies that are similar to ORIC Pharmaceuticals include UroGen Pharma, Assertio, Satsuma Pharmaceuticals, Savara and Silverback Therapeutics. Learn More about companies similar to ORIC Pharmaceuticals.

How do I contact ORIC Pharmaceuticals' investor relations team?

ORIC Pharmaceuticals' physical mailing address is 240 E. GRAND AVE. 2ND FLOOR, SOUTH SAN FRANCISCO CA, 94080. The company's listed phone number is 650-388-5600 and its investor relations email address is [email protected] The official website for ORIC Pharmaceuticals is www.oricpharma.com. Learn More about contacing ORIC Pharmaceuticals investor relations.